Direct Biologics announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct Biologics is the first and only EV company to receive FDA Phase 3 approval for an Investigational New Drug…
eTurboNews greinar eru eingöngu fyrir áskrifendur. Áskrift er FRJÁLS.
Áskrifendur skrá sig hér Smelltu hér til að gerast áskrifandi ÓKEYPIS
Áskrifendur skrá sig hér Smelltu hér til að gerast áskrifandi ÓKEYPIS
HVAÐ Á AÐ TAKA ÚR ÞESSARI GREIN:
- Direct Biologics is the first and only EV company to receive FDA Phase 3 approval for an Investigational New Drug….
- Direct Biologics announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19.
- eTurboNews greinar eru eingöngu fyrir áskrifendur.
